Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Ferric Carboxymaltose vs Standard Care in Iron Deficiency Anemia
NCT00703937Phase 3Completed
- Sponsor
- American Regent, Inc.
- Start
- Jul 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric carboxymaltose in iron deficiency anemia (IDA) (2 arms), sponsored by American Regent, Inc. Primary endpoint: Occurrence of Serious Adverse Events at Day 42. Started Jul 2008; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT00703937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00703937.